SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

☑ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person*
Sanofi

(Last) (First) (Middle)
46 AVENUE DE LA GRANDE ARMEE

(Street)
PARIS 75017

(City) (State) (Zip)
FRANCE

(Country)

2. Issuer Name **and** Ticker or Trading Symbol
Latigo Biotherapeutics, Inc. [LTGO]
Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Director
☑ 10% Owner
Officer (give title below)
Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
☑ Form filed by One Reporting Person
Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/10/2026		C		494,800	A	(1)	494,800	I(3)	See footnote(3)
Common Stock	08/10/2026		C		177,978	A	(2)	672,788	I(3)	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B Preferred Stock	(1)	08/10/2026		C			494,800	(1)	(1)	Common Stock	494,800	(1)	0	I(3)	See footnote(3)
Convertible Promissory Note	(2)	08/10/2026		C			177,978	(2)	(2)	Common Stock	177,978	(2)	0	I(3)	See footnote(3)

Explanation of Responses:

1. The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration.
2. The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock.
3. Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.

Remarks:

Immediately upon consummation of the IPO, Sanofi's beneficial ownership of the common stock fell below 10%, as a result of the issuance of additional shares of common stock. The convertibility and expiration of the Preferred Stock and Note prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 12, 2026.

/s/ Alexandra Roger, as attorney-in-fact for Sanofi	08/12/2026
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.